Loading...
XOSLPHO
Market cap149mUSD
Dec 20, Last price  
64.00NOK
1D
2.73%
1Q
21.21%
Jan 2017
52.38%
Name

Photocure ASA

Chart & Performance

D1W1MN
XOSL:PHO chart
P/E
6,497.24
P/S
3.46
EPS
0.01
Div Yield, %
0.00%
Shrs. gr., 5y
4.64%
Rev. gr., 5y
22.50%
Revenues
501m
+27.35%
77,809,00053,641,000210,320,00099,006,000102,220,00048,428,000177,357,000115,568,000133,823,00083,616,000128,952,000134,717,000143,627,000150,911,000181,510,000281,556,000256,482,000360,540,000393,132,000500,657,000
Net income
979k
P
-45,031,000-38,210,00085,082,000-74,970,000-64,382,000312,382,00018,092,000-7,512,000-47,901,000-58,950,000-24,700,000-36,178,00035,309,000-34,697,000-36,708,00031,832,000-22,403,000-30,897,000-71,857,000979,000
CFO
48m
P
-50,248,000-70,540,00066,326,000-95,655,000-59,677,000317,444,00015,597,000-34,466,000-54,928,000-99,722,000-6,088,000-21,032,00019,193,000-23,593,000-24,124,00020,655,00015,585,00023,886,000-2,018,00048,309,000
Dividend
May 23, 20132 NOK/sh
Earnings
Feb 19, 2025

Profile

Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
URL
https://photocure.com/
IPO date
May 29, 2000
Employees
87
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
500,657
27.35%
393,132
9.04%
360,540
40.57%
Cost of revenue
375,762
329,473
288,239
Unusual Expense (Income)
NOPBT
124,895
63,659
72,301
NOPBT Margin
24.95%
16.19%
20.05%
Operating Taxes
8,761
723
(759)
Tax Rate
7.01%
1.14%
NOPAT
116,134
62,936
73,060
Net income
979
-101.36%
(71,857)
132.57%
(30,897)
37.91%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,580
14,042
BB yield
-0.26%
-0.51%
Debt
Debt current
5,613
18,282
30,831
Long-term debt
33,561
48,294
65,957
Deferred revenue
Other long-term liabilities
132,003
130,989
137,119
Net debt
(217,162)
(198,075)
(222,251)
Cash flow
Cash from operating activities
48,309
(2,018)
23,886
CAPEX
(12,306)
(3,609)
(3,703)
Cash from investing activities
(594)
(1,462)
(1,896)
Cash from financing activities
(56,284)
(51,342)
(33,983)
FCF
90,823
68,147
52,051
Balance
Cash
256,336
264,651
319,039
Long term investments
Excess cash
231,303
244,994
301,012
Stockholders' equity
22,276
22,436
91,899
Invested Capital
612,162
606,237
611,996
ROIC
19.06%
10.33%
12.27%
ROCE
19.69%
10.13%
10.27%
EV
Common stock shares outstanding
27,133
27,035
26,843
Price
67.40
-36.89%
106.80
3.99%
102.70
-3.66%
Market cap
1,828,798
-36.66%
2,887,336
4.73%
2,756,810
5.04%
EV
1,611,636
2,689,261
2,536,643
EBITDA
152,582
88,037
96,428
EV/EBITDA
10.56
30.55
26.31
Interest
26,327
25,804
23,826
Interest/NOPBT
21.08%
40.53%
32.95%